Clinical Trial

XVIVO Heart Transplant Study in Clinical Practice

Study acronym: HOPE for All
Recruiting
View on ClinicalTrials.gov →
Summary
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting. The trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient. The hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation. Primary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation. Secondary objective(s) are to evaluate patient outcomes and graft function post-transplant. HOPE for All is a prospective, single-armed single-centre proof-of-consept trial.
Trial Details
NCT Number NCT07556588
Lead Sponsor XVIVO Perfusion
Conditions Heart Failure
Enrollment 20 participants
Start Date 2024-08-03
Primary Completion 2027-05-15 (estimated)
Study Completion 2028-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12